HC Wainwright maintains $165 price target for Corcept Therapeutics
HC Wainwright & Co. maintained a $165.00/share price target for Corcept Therapeutics, per Benzinga ratings coverage.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.